Related Experiment Video
Updated: Jul 28, 2026
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
[New antithrombotic therapy approaches in coronary heart disease--prospects for gene therapy]
T W Jax1, H C Eichstaedt, H S Shelat
1Cullen Cardiovascular Surgical Research Laboratories, Texas Heart Institute, Houston, Texas, USA.
Abstract:
Despite considerable progress, pharmacological therapies have not provided a complete solution for common cardiovascular problems, including recurrent thrombosis, restenosis, and vein graft deterioration. Optimal drug dosage, reproducing plasma concentrations achieved in animal studies establishing proof-of-principle, would often be too toxic to administer. Local gene therapy aims at overexpressing proteins that regulate the cell cycle of vascular smooth muscle cells, inhibit vascular smooth muscle cell migration, endow the endothelium with enhanced vasoprotective properties. Alternatively, some approaches tend to suppress gene expression of proteins believed to promote vascular smooth muscle cell proliferation and migration. In sharp contrast to drug treatments, local gene therapy limits expression of the beneficial agent to the injured vascular site, where it can extend the presence of this agent to weeks and, with some gene vectors, to many months. This review summarizes and discusses antithrombotic gene therapy approaches for the prevention of restenosis and late thrombosis after catheter-based revascularizations.
Insights
Local gene therapy offers a promising alternative to traditional drugs for cardiovascular issues like restenosis and thrombosis. This approach targets specific genes at injury sites, providing localized, long-lasting therapeutic effects.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Gene Therapy
Context:
- Pharmacological treatments for cardiovascular diseases like thrombosis and restenosis have limitations.
- Achieving effective drug concentrations often leads to unacceptable toxicity.
- Existing therapies fail to fully address issues such as recurrent thrombosis and vein graft deterioration.
Purpose:
- To review and discuss local gene therapy strategies for preventing restenosis and late thrombosis after revascularization procedures.
- To highlight the advantages of gene therapy over conventional pharmacological treatments in cardiovascular medicine.
- To explore gene therapy's potential in regulating vascular smooth muscle cell behavior and enhancing endothelial function.
Summary:
- Local gene therapy involves overexpressing or suppressing specific genes to regulate vascular smooth muscle cell proliferation and migration.
- Gene therapy can endow the endothelium with enhanced vasoprotective properties.
- Unlike systemic drug administration, local gene therapy confines therapeutic agent expression to the injured vascular site, offering prolonged local presence (weeks to months).
Impact:
- Gene therapy presents a targeted and potentially less toxic approach to managing cardiovascular conditions.
- This strategy could improve outcomes for patients undergoing catheter-based revascularizations by preventing restenosis and thrombosis.
- Local gene therapy offers a sustained therapeutic effect at the site of vascular injury, overcoming limitations of systemic drug delivery.
Related Concept Videos
00:59Gene Therapy
00:59Gene Therapy
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:29Pharmacogenomics: Identification of New Drug Targets
01:26Atherosclerosis III: Management